Evidence map›Paper›PMID 29500764›Full record

ArticleAnnals of surgical oncology2018

The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.

Emily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, Jennifer A Wargo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [European journal of nuclear medicine and molecular imaging · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Emily Z KeungDepartment of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Esosa U UkponmwanDepartment of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexandria P CogdillDepartment of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoDepartment of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

TRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2M
Exploring synergy of combined BRAF-targeted therapy & immunotherapy for melanomaK08CA160692 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2012 to 2016
$713k
NCI NIH HHS K08 CA160692NCI NIH HHS T32 CA009599
6 · The paper itself

Abstract

Unprecedented advances in the treatment of cancer have occurred through the use of immunotherapy, with several agents currently approved by the Food and Drug Administration (FDA) for the treatment of widespread metastatic disease across cancer types. Immune checkpoint blockade represents a particularly promising class of agents that block inhibitory molecules on the surface of T cells, resulting in their activation and propagation of an immune response. Treatment with these agents may re-invigorate anti-tumor immunity, resulting in therapeutic responses, and use of these agents currently is being studied in the adjuvant setting. Additionally, a strong rationale exists for their use in the neoadjuvant setting for high-risk resectable disease (e.g., regional nodal disease in the case of melanoma). This rationale is based on the relatively high risk of relapse for these patients, as well as on scientific evidence suggesting that long-term immunologic memory and tumor control may be superior in the setting of treatment for an intact tumor (i.e., neoadjuvant therapy) as opposed to treatment in the setting of micrometastatic disease (e.g., adjuvant treatment). The potential advantages of this approach and the current landscape for neoadjuvant immune checkpoint blockade is discussed in this report, as well as caveats that should be considered by clinicians contemplating this strategy.

Indexed as

ImmunotherapyNeoadjuvant TherapyAntibodies, MonoclonalB7-H1 AntigenHumansNeoplasmsAntibodies, MonoclonalB7-H1 AntigenCD274 protein, human

Identifiers

PMID29500764
PMCPMC6105272
OpenAlexW2789830121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.